Can MRI scans reveal how diabetes drugs shield kidneys?

NCT ID NCT07270198

Not yet recruiting Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will use advanced MRI scans and blood tests to explore how SGLT2i medications protect the kidneys in 100 people with diabetic kidney disease who are at risk of worsening. Participants will already be taking SGLT2i as part of their routine care. The goal is to identify markers that predict which patients will have slower kidney decline, helping tailor future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients with diabetic kidney disease will benefit most from SGLT2i therapy, potentially slowing kidney decline.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE (DKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE (DKD)

Contacts and locations

Locations

Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.